Early switching from intravenous to oral antibiotic therapy in bone and joint infections associated with methicillin-susceptible Staphylococcus aureus bacteremia - Université de Reims Champagne-Ardenne Access content directly
Journal Articles Infectious Diseases Now Year : 2023

Early switching from intravenous to oral antibiotic therapy in bone and joint infections associated with methicillin-susceptible Staphylococcus aureus bacteremia

Abstract

Objectives: We aimed to evaluate the clinical outcomes of patients with bone and joint infection (BJI) associated with methicillin-susceptible Staphylococcus aureus bacteremia (MSSAB) treated with early oral switch to oral antibiotics (before day 14) versus later or no switch. Patients and methods: We included all cases reported between January 2016 and December 2021 in the University Hospital of Reims. Results: Among 79 patients with BJI associated with MSSAB, 50.6% had an early switch to oral antibiotics, with median duration of intravenous antibiotics of 9 (IQR 6–11) days. The overall cure rate was 81% with follow-up of 6 months, and was 85.7% after excluding the 9 patients whose death was not related to BJI infection. Failure to control BJI did not differ between the two groups. Conclusion: An early (before day 14) switch to oral antibiotics may be a safe therapeutic option in BJI associated with MSSAB.

Dates and versions

hal-04179602 , version 1 (10-08-2023)

Identifiers

Cite

Maïwenn Petithomme-Nanrocki, Véronique Vernet-Garnier, Delphine Lebrun, Odile Bajolet, Morgane Bonnet, et al.. Early switching from intravenous to oral antibiotic therapy in bone and joint infections associated with methicillin-susceptible Staphylococcus aureus bacteremia. Infectious Diseases Now, 2023, 53 (6), pp.104739. ⟨10.1016/j.idnow.2023.104739⟩. ⟨hal-04179602⟩

Collections

URCA P3CELL VIEFRA
16 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More